Childhood cancer epidemiology in low‐income countries

Global studies of childhood cancer provide clues to cancer etiology, facilitate prevention and early diagnosis, identify biologic differences, improve survival rates in low‐income countries (LIC) by facilitating quality improvement initiatives, and improve outcomes in high‐income countries (HIC) through studies of tumor biology and collaborative clinical trials. Incidence rates of cancer differ between various ethnic groups within a single country and between various countries with similar ethnic compositions. Such differences may be the result of genetic predisposition, early or delayed exposure to infectious diseases, and other environmental factors. The reported incidence of childhood leukemia is lower in LIC than in more prosperous countries. Registration of childhood leukemia requires recognition of symptoms, rapid access to primary and tertiary medical care (a pediatric cancer unit), a correct diagnosis, and a data management infrastructure. In LIC, where these services are lacking, some children with leukemia may die before diagnosis and registration. In this environment, epidemiologic studies would seem to be an unaffordable luxury, but in reality represent a key element for progress. Hospital‐based registries are both feasible and essential in LIC, and can be developed using available training programs for data managers and the free online Pediatric Oncology Networked Data Base (www.POND4kids.org), which allows collection, analysis, and sharing of data. Cancer 2008. © 2007 American Cancer Society.

[1]  W. Mcdougal An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. , 2002, The Journal of urology.

[2]  M. Dyer,et al.  Use of Preclinical Models to Improve Treatment of Retinoblastoma , 2005, PLoS medicine.

[3]  B. Figueiredo,et al.  [Childhood adrenocortical tumors]. , 1997, Arquivos brasileiros de endocrinologia e metabologia.

[4]  C. Pui,et al.  Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil , 2007, Pediatric blood & cancer.

[5]  P. Boffetta,et al.  Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation , 2005, Journal of Medical Genetics.

[6]  M. Greaves Infection, immune responses and the aetiology of childhood leukaemia , 2006, Nature Reviews Cancer.

[7]  J. Potter,et al.  Maternal Diet and Infant Leukemia: The DNA Topoisomerase II Inhibitor Hypothesis: A Report from the Children's Oncology Group , 2005, Cancer Epidemiology Biomarkers & Prevention.

[8]  J. Drake,et al.  Impact of telemedicine on pediatric neuro‐oncology in a developing country: The Jordanian‐Canadian experience , 2007, Pediatric blood & cancer.

[9]  C. Pui,et al.  Improving outcomes for children with cancer in low‐income countries in Latin America: A report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)‐Part I , 2007, Pediatric blood & cancer.

[10]  R. Ribeiro,et al.  Impact of an education program on late diagnosis of retinoblastoma in Honduras , 2007, Pediatric blood & cancer.

[11]  M. Valsecchi,et al.  Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements , 2005, Leukemia.

[12]  K. Bhatia,et al.  Association of Burkitt's Lymphoma with the Epstein-Barr Virus in Two Developing Countries , 2000, Leukemia & lymphoma.

[13]  C. Rodríguez-Galindo,et al.  Protocol‐based treatment for children with cancer in low income countries in Latin America: A report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)—Part II , 2007, Pediatric blood & cancer.

[14]  L. Robison,et al.  Birth Characteristics, Maternal Reproductive History, and the Risk of Infant Leukemia: A Report from the Children's Oncology Group , 2007, Cancer Epidemiology Biomarkers & Prevention.

[15]  G. Masera,et al.  A survey of resources and activities in the MISPHO family of institutions in Latin America: A comparison of two eras , 2004, Pediatric blood & cancer.

[16]  J. Burchenal,et al.  Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.

[17]  C. Gundy,et al.  Influence of Socioeconomic Status on Childhood Acute Lymphoblastic Leukemia Treatment in Indonesia , 2006, Pediatrics.

[18]  D. Venzon,et al.  Preliminary report of an intensified, short duration chemotherapy protocol for the treatment of pediatric non-Hodgkin's lymphoma in India. , 1997, Annals of Oncology.

[19]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[20]  N. Laurie,et al.  Topotecan combination chemotherapy in two new rodent models of retinoblastoma (Clinical Cancer Research (2005) 11 (7569-7578)) , 2009 .

[21]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[22]  M. Relling,et al.  Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma , 2005, Clinical Cancer Research.

[23]  M. Louw,et al.  The 2000 Burkitt lymphoma trial in Malawi , 2005, Pediatric blood & cancer.

[24]  L. Clegg,et al.  SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. , 2002, Medical and pediatric oncology.

[25]  W. Furlong,et al.  Health status and health-related quality of life in survivors of cancer in childhood in Latin America: a MISPHO feasibility study. , 2001, International journal of oncology.

[26]  R. Ribeiro,et al.  Pediatric Oncology in Countries with Limited Resources , 1997 .

[27]  Daniel Sinnett,et al.  Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. , 2007, Blood.

[28]  Yuri Quintana,et al.  Implementation of a data management program in a pediatric cancer unit in a low income country , 2007, Pediatric blood & cancer.

[29]  C. Pui,et al.  Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. , 2004, JAMA.

[30]  D. Venzon,et al.  Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year peroid , 2005 .

[31]  C. Pui,et al.  Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries , 2003, The Lancet.

[32]  L. Kinlen Infections and immune factors in cancer: the role of epidemiology , 2004, Oncogene.

[33]  C. Pui,et al.  Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop , 2004, Leukemia.

[34]  K. Naresh,et al.  Discrepancies in Epstein-Barr virus association at presentation and relapse of classical Hodgkin's disease: impact on pathogenesis. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  S. Kayed,et al.  The incidence of childhood cancer in Jordan: a population-based study. , 2003, Annals of Saudi medicine.

[36]  C. Rodríguez-Galindo,et al.  Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  G. Morgan,et al.  Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. , 2002, Blood.

[38]  D. Campana,et al.  Development of a regional flow cytometry center for diagnosis of childhood leukemia in Central America , 2005, Leukemia.

[39]  R. W. Miller Epidemiologic evidence for genetic variability in the frequency of cancer: ethnic differences. , 1988, Basic life sciences.

[40]  D. Venzon,et al.  Acute lymphoblastic leukemia in India: an analysis of prognostic factors using a single treatment regimen. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Miller Rw Geographical and ethnic differences in the occurrence of childhood cancer. , 1988 .

[42]  M. Relling,et al.  TOPOISOMERASE II INHIBITOR‐RELATED ACUTE MYELOID LEUKAEMIA , 2000, British journal of haematology.

[43]  M. Dyer,et al.  The first knockout mouse model of retinoblastoma. , 2006, Cell cycle.

[44]  I. Magrath Non‐Hodgkin's Lymphomas: Epidemiology and Treatment , 1997, Annals of the New York Academy of Sciences.

[45]  P. Forgeron,et al.  Pediatric pain prevalence and parents' attitudes at a cancer hospital in Jordan. , 2006, Journal of pain and symptom management.

[46]  F. Carrión,et al.  Establishment of a pediatric HSCT program in a public hospital in Chile , 2006, Pediatric blood & cancer.

[47]  D. Parkin,et al.  The international incidence of childhood cancer , 1988, IARC scientific publications.

[48]  D. Venzon,et al.  Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected]. , 2005, European journal of cancer.

[49]  P. Luthert,et al.  Outcome of retinoblastoma in east Africa , 2008, Pediatric blood & cancer.

[50]  F. Berrino,et al.  Childhood cancer survival trends in Europe: a EUROCARE Working Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[52]  R. Ribeiro,et al.  A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer , 2002, Nature Structural Biology.